Back
AT1-receptor antagonism in hypertension: what has been learned with irbesartan?
Journal article

AT1-receptor antagonism in hypertension: what has been learned with irbesartan?

  • Waeber B University Hospital, Division of Pathophysiology, Lausanne, Switzerland. bwaeber@chuv.hospvd.ch
  • Burnier M
  • 2004-03-20
Published in:
  • Expert review of cardiovascular therapy. - 2003
Angiotensin II Type 1 Receptor Blockers
Antihypertensive Agents
Biphenyl Compounds
Blood Pressure
Humans
Hypertension
Irbesartan
Tetrazoles
English Irbesartan is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor). This compound lowers blood pressure dose-dependently in hypertensive patients and has a placebo-like tolerability. The antihypertensive efficacy of irbesartan is greatly enhanced by the coadministration of a diuretic, and fixed-dose combinations of irbesartan and hydrochlorothiazide are now available. Irbesartan-based treatment appears especially effective for high-risk patients, such as those with diabetes, renal disease and cardiac hypertrophy. In patients with Type 2 diabetes, irbesartan delays the development of nephropathy as well as the progression of renal failure. Irbesartan may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of angiotensin II. Irbesartan given alone or in combination with a diuretic therefore represents a rational approach to treat hypertensive patients.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/139238
Statistics
Document views: 12 File downloads: